Burning Rock Biotech

Burning Rock Biotech is a Guangzhou, China-based precision-oncology diagnostics company applying next-generation sequencing (NGS) to cancer therapy selection and early detection. Its product line spans OncoScreen and OncoCompass tissue and liquid-biopsy tests for lung and pan-cancer applications, ColonCore for gastrointestinal MSI/mutation assessment, and CanCatch, a ctDNA platform for pre-operative detection and post-operative minimal residual disease monitoring, with U.S. patent coverage granted in 2026. The company operates central-laboratory, in-hospital, and pharma R&D-service segments, in-licensed Myriad Genetics' myChoice testing for China, and collaborates with AstraZeneca, Bayer, Johnson & Johnson, BeiGene, Boehringer Ingelheim and others on clinical research. Burning Rock listed on Nasdaq in June 2020 and reported Q1 2026 revenue of RMB107.9 million (US$15.6 million).